Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY pelareorep + CD3 bispecific antibody true-killer combo

<< Previous

Bullboard Posts

Next >>

Comment by CaseyLon Sep 13, 2024 10:28am

280 Views

Post# 36222138

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY pelareorep + CD3 bispecific antibody true-killer combo

By the looks, they have six phase 3 trials with a management that did not run the company in the ground. I think our current share price/value is about right. ONCY's management is a huge disappointment.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Nov. 25, 2024